相关实验视频
Updated: Jul 21, 2025

14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
9.6K
针对突变的p53稳定用于癌症治疗
Jiajian Wang1, Wenjun Liu1, Lanqing Zhang1
1Medical School, Kunming University of Science and Technology, Kunming, China.
Frontiers in pharmacology
|July 28, 2023
概括
突变的p53蛋白质积累驱动癌症的进展. 针对其异常稳定性,由伴侣和其他分子调节,提供了一个有前途的癌症治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 超过50%的癌症携带TP53突变,导致高度稳定的突变p53蛋白.
- 突变p53通过功能丧失,主导负效应和功能增益机制促进瘤发生.
- 异常突变的p53稳定性是由无素蛋白酶体系统和分子伴侣所调节的.
研究的目的:
- 审查突变p53稳定背后的机制.
- 讨论用于癌症治疗的操纵这些稳定过程的策略.
主要方法:
- 关于突变p53稳定通路的文献综述.
- 对分子伴侣 (Hsp40,Hsp70,Hsp90) 和生物分子 (TRIM21,BAG2,Stat3) 的调节作用的分析.
- 检查突变的p53聚合和复合形成.
主要成果:
- 突变p53的积累主要由分子伴侣和其他生物分子调节.
- 类聚合和蛋白质复合体形成有助于突变p53在瘤细胞中的积累.
- 削弱突变p53是一种新兴的治疗策略.
结论:
- 了解突变p53稳定机制对于开发向癌症疗法至关重要.
- 操纵伴侣相互作用和聚合途径具有治疗潜力.
- 针对突变的p53稳定性是癌症治疗的可行策略.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K

